Neuland Laboratories Limited announces commercial production start of expanded capacities
Neuland Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Commercial production commenced for additional capacities at Unit 1 and Unit 3.
- Unit 1 located in Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana.
- Unit 3 located in Gaddapotharam Village, Jinnaram Mandal, Sangareddy District, Telangana.
Why it's rated notable: Commercial production has started at two units under expansion plans, but the filing states no capex or revenue amount, so the level stays at medium.
Original filing
Intimation Under Regulation 30 Of SEBI Listing Regulations
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Neuland Laboratories
- Financial resultsMajor developmentNeuland Q1 net profit up to ₹14,767.31 lakhs; Gland guarantee, Unit 1 capex approved
- Capex / expansionMajor developmentNeuland Laboratories reports Q1 FY 2027 results and announces Gland Pharma partnership
- Capex / expansionMajor developmentNeuland Q1 profit 14,767.31 lakhs vs 1,390.00 lakhs; Gland Pharma sterile API tie-up
- Financial resultsMajor developmentNeuland Labs: FY26 results, ₹34 dividend, capacity expansion, new director
- Dividend / buyback / bonusMajor developmentNeuland Laboratories approves FY26 audited results, ₹34 dividend, director appointment
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.